1. Exploration of the Nanomedicine-Design Space with High-throughput Screening and Machine Learning*
- Author
-
Albert Y. Xue, Eric J. Berns, Chad A. Mirkin, Andrew Lee, Milan Mrksich, Neda Bagheri, and Gokay Yamankurt
- Subjects
0301 basic medicine ,Computer science ,High-throughput screening ,Oligonucleotides ,Biomedical Engineering ,Medicine (miscellaneous) ,Bioengineering ,Machine learning ,computer.software_genre ,Article ,Cell Line ,Machine Learning ,Structure-Activity Relationship ,03 medical and health sciences ,0302 clinical medicine ,Nucleic Acids ,Animals ,Humans ,Screening tool ,Analysis method ,business.industry ,Extramural ,Scale (chemistry) ,Alkaline Phosphatase ,High-Throughput Screening Assays ,Computer Science Applications ,Nanomedicine ,030104 developmental biology ,Liposomes ,Nanoparticles ,Artificial intelligence ,business ,Design space ,computer ,030217 neurology & neurosurgery ,Biotechnology ,Immune activation - Abstract
Only a tiny fraction of the nanomedicine-design space has been explored, owing to the structural complexity of nanomedicines and the lack of relevant high-throughput synthesis and analysis methods. Here, we report a methodology for determining structure–activity relationships and design rules for spherical nucleic acids (SNAs) functioning as cancer-vaccine candidates. First, we identified ~1,000 candidate SNAs on the basis of reasonable ranges for 11 design parameters that can be systematically and independently varied to optimize SNA performance. Second, we developed a high-throughput method for making SNAs at the picomolar scale in a 384-well format, and used a mass spectrometry assay to rapidly measure SNA immune activation. Third, we used machine learning to quantitatively model SNA immune activation and identify the minimum number of SNAs needed to capture optimum structure–activity relationships for a given SNA library. Our methodology is general, can reduce the number of nanoparticles that need to be tested by an order of magnitude, and could serve as a screening tool for the development of nanoparticle therapeutics.
- Published
- 2020
- Full Text
- View/download PDF